C WorldWide Group Holding A S boosted its stake in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) by 17.7% during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 89,549 shares of the company’s stock after buying an additional 13,458 shares during the period. C WorldWide Group Holding A S’s holdings in Aerie Pharmaceuticals were worth $4,706,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of AERI. BlackRock Inc. boosted its position in Aerie Pharmaceuticals by 113,376.8% in the first quarter. BlackRock Inc. now owns 2,600,888 shares of the company’s stock valued at $117,951,000 after buying an additional 2,598,596 shares in the last quarter. Russell Investments Group Ltd. boosted its position in Aerie Pharmaceuticals by 813.5% in the second quarter. Russell Investments Group Ltd. now owns 232,610 shares of the company’s stock valued at $12,223,000 after buying an additional 207,146 shares in the last quarter. FMR LLC boosted its position in Aerie Pharmaceuticals by 178.7% in the first quarter. FMR LLC now owns 320,500 shares of the company’s stock valued at $14,535,000 after buying an additional 205,500 shares in the last quarter. Suffolk Capital Management LLC boosted its position in Aerie Pharmaceuticals by 753.3% in the second quarter. Suffolk Capital Management LLC now owns 145,853 shares of the company’s stock valued at $7,665,000 after buying an additional 128,760 shares in the last quarter. Finally, Vanguard Group Inc. boosted its position in Aerie Pharmaceuticals by 7.1% in the first quarter. Vanguard Group Inc. now owns 1,392,525 shares of the company’s stock valued at $63,151,000 after buying an additional 92,463 shares in the last quarter. 92.98% of the stock is owned by institutional investors.

Shares of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) opened at 51.45 on Friday. The company’s 50-day moving average price is $54.69 and its 200 day moving average price is $47.93. Aerie Pharmaceuticals, Inc. has a 12-month low of $17.84 and a 12-month high of $59.50. The company’s market cap is $1.87 billion.

Aerie Pharmaceuticals (NASDAQ:AERI) last released its quarterly earnings results on Tuesday, August 1st. The company reported ($0.82) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.84) by $0.02. Equities analysts predict that Aerie Pharmaceuticals, Inc. will post ($2.56) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “C WorldWide Group Holding A S Purchases 13,458 Shares of Aerie Pharmaceuticals, Inc. (AERI)” was published by Daily Political and is owned by of Daily Political. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this news story can be accessed at https://www.dailypolitical.com/2017/08/11/c-worldwide-group-holding-a-s-purchases-13458-shares-of-aerie-pharmaceuticals-inc-aeri.html.

Several research analysts have recently weighed in on AERI shares. Zacks Investment Research cut Aerie Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, July 11th. HC Wainwright reaffirmed a “buy” rating and set a $69.00 price objective on shares of Aerie Pharmaceuticals in a research report on Thursday, May 25th. BidaskClub cut Aerie Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, June 17th. Canaccord Genuity reaffirmed a “buy” rating and set a $56.00 price objective on shares of Aerie Pharmaceuticals in a research report on Tuesday, April 18th. Finally, Stifel Nicolaus reaffirmed a “buy” rating on shares of Aerie Pharmaceuticals in a research report on Friday, May 26th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. Aerie Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $66.08.

In other Aerie Pharmaceuticals news, major shareholder Foresite Capital Fund Ii, L.P. sold 20,000 shares of Aerie Pharmaceuticals stock in a transaction dated Friday, May 26th. The stock was sold at an average price of $55.95, for a total transaction of $1,119,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 9.36% of the stock is currently owned by insiders.

About Aerie Pharmaceuticals

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).

Want to see what other hedge funds are holding AERI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aerie Pharmaceuticals, Inc. (NASDAQ:AERI).

Institutional Ownership by Quarter for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.